Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.

@article{Hiemke2017ConsensusGF,
  title={Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.},
  author={Christoph Hiemke and Niels Bergemann and Hans Willi Clement and Andreas Conca and J{\"u}rgen Deckert and Katharina Domschke and Gabriel Eckermann and Karin Egberts and Manfred Gerlach and Christine Greiner and Gerhard Gruender and Ekkerhard Haen and Ursula Havemann-Reinecke and Gudrun Hefner and Renate Helmer and Ger Janssen and Eveline Jaquenoud and Gerd Laux and Thomas M. Messer and Rainald Moessner and Matthias J. M{\"u}ller and Michael Paulzen and Bruno Pfuhlmann and Peter Franz Riederer and Alois Saria and Bernd Schoppek and Georgios Schoretsanitis and Markus J. Schwarz and Margarete Silva Gracia and Benedikt Stegmann and Werner Steimer and Julia C. Stingl and M. Uhr and Sven Ulrich and Stefan Unterecker and Roland Waschgler and Gerald Zernig and Gabriela Zurek and Pierre Baumann},
  journal={Pharmacopsychiatry},
  year={2017},
  volume={51 1-02},
  pages={
          9-62
        }
}
Therapeutic drug monitoring (TDM) is the quantification and interpretation of drug concentrations in blood to optimize pharmacotherapy. It considers the interindividual variability of pharmacokinetics and thus enables personalized pharmacotherapy. In psychiatry and neurology, patient populations that may particularly benefit from TDM are children and adolescents, pregnant women, elderly patients, individuals with intellectual disabilities, patients with substance abuse disorders, forensic… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 26 CITATIONS

Pharmacokinetic correlates of venlafaxine: associated adverse reactions

  • European Archives of Psychiatry and Clinical Neuroscience
  • 2019
VIEW 4 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

Utility of Duloxetine Dose-Related Reference Ranges Calculated by AGNP Consensus Guidelines 2017

G. Hefner, M. Hahn, M. Buenger, S. C. Roll
  • 2019
VIEW 9 EXCERPTS
CITES METHODS, BACKGROUND & RESULTS
HIGHLY INFLUENCED

Antidepressants in breast milk; comparative analysis of excretion ratios

  • Archives of Women's Mental Health
  • 2018
VIEW 9 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Influence of dose, gender, and cigarette smoking on clozapine plasma concentrations

  • Neuropsychiatric disease and treatment
  • 2018
VIEW 8 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Therapeutisches Drug-Monitoring in der Neuropsychopharmakologie

VIEW 10 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Behandlung von ADHS bei Erwachsenen mit Atomoxetin

  • psychopraxis. neuropraxis
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 1,348 REFERENCES

Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin

S Härtter, X Wang, H Weigmann
  • J Clin Psychopharmacol
  • 2001
VIEW 35 EXCERPTS
HIGHLY INFLUENTIAL

Metabolism of the antidepressant mirtazapine in vitro: Contribution of cytochromes P-450 1A2, 2D6, and 3A4

E Stormer, LL von Moltke, RI Shader
  • Drug Metab Dispos
  • 2000
VIEW 84 EXCERPTS
HIGHLY INFLUENTIAL

Effects of 22 novel CYP2D6 variants found in Chinese population on the metabolism of dapoxetine

  • Drug design, development and therapy
  • 2016
VIEW 84 EXCERPTS
HIGHLY INFLUENTIAL

The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part I: A summary of the current state for clinicians

J. de Leon
  • Rev Psiquiatr Salud Ment 2015;
  • 2015
VIEW 16 EXCERPTS
HIGHLY INFLUENTIAL

Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6.

  • Xenobiotica; the fate of foreign compounds in biological systems
  • 2014
VIEW 84 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…